Evidence map›Paper›PMID 26546609›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during Chronic HIV Infection.

Rafael Cubas, Julien van Grevenynghe, Saintedym Wills, Lela Kardava, Brian H Santich, Clarisa M Buckner, Roshell Muir, Virginie Tardif, Carmen Nichols, Francesco Procopio and 17 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 71 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Interleukin-21 in Viral Infections.International journal of molecular sciences · 2021
    Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 10 institutions in 3 countries.

Rafael CubasVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;
Julien van GrevenyngheInstitut National de la Recherche Scientifique, Institut Armand-Frappier, Laval H7V 1B7, Quebec, Canada;ORCID http://orcid.org/0000-0002-2952-4081
Saintedym WillsDepartment of Immunology and the Duke Human Vaccine Institute, Duke University, Durham, NC 27710;ORCID http://orcid.org/0000-0003-2379-8679
Lela KardavaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;ORCID http://orcid.org/0000-0001-9135-6026
Brian H SantichLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;ORCID http://orcid.org/0000-0001-5869-3661
Clarisa M BucknerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;ORCID http://orcid.org/0000-0002-8178-8076
Roshell MuirVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;
Virginie TardifVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;
Carmen NicholsVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;ORCID http://orcid.org/0000-0003-0364-9625
Francesco ProcopioService d'Immunologie et Allergie, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland;
Zhong HeVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;ORCID http://orcid.org/0000-0002-7369-9989
Talibah MetcalfVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;
Khader GhneimVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;ORCID http://orcid.org/0000-0003-0548-1942
Michela LocciDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037;
Petronella AncutaDepartment of Medicine, University of Montreal, Montreal, Quebec H3C 3J7, Canada; Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, University of Montreal, Montreal, Quebec H3C 3J7, Canada;ORCID http://orcid.org/0000-0003-1922-5640
Jean-Pierre RoutyChronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec H3H 2R9, Canada; Research Institute, McGill University Health Centre, Montreal, Quebec H3H 2R9, Canada; Division of Hematology, McGill University Health Centre, Montreal, Quebec H3H 2R9, Canada;
Lydie TrautmannVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;
Yuxing LiInternational AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037;
Adrian B McDermottImmunology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;
Rick A KoupImmunology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;
Constantinos PetrovasImmunology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;
Steven A MiguelesHIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;
Mark ConnorsHIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;
Georgia D TomarasDepartment of Immunology and the Duke Human Vaccine Institute, Duke University, Durham, NC 27710;
Susan MoirLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;
Shane CrottyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA 92093; and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, La Jolla, CA 92037.
Elias K HaddadVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987; elias.elhaddad@drexelmed.edu.
National Institutes of Health · USVaccine & Gene Therapy Institute of Florida · USDuke University · USInstitut National de la Recherche Scientifique · CAInternational AIDS Vaccine Initiative · USLa Jolla Institute for Immunology · USMcGill University Health Centre · CAScripps Research Institute · USUniversité de Montréal · CAUniversity Hospital of Lausanne · CH

Funding

LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Role of B Lymphocytes In HIV Infection And PathogenesisZIAAI000825 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOIR, SUSAN · 2009 to 2025
$24.5M
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNPZIAAI000855 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CONNORS, MARK · 2009 to 2025
$20.0M
Mechanisms of Effective Humoral Immune Responses to HIV-1ZIAAI001090 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CONNORS, MARK · 2009 to 2025
$14.8M
Non-Human PrimatesP01AI104722 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WYATT, RICHARD THOMAS · 2014 to 2018
$14.6M
High-resolution definition of B cell responses to HIV Env for immunogen designR01AI102766 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LI, YUXING · 2013 to 2024
$6.6M
Basic Immunology Training ProgramT32AI052077 · NIAID · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2002 to 2024
$4.2M
Boosting anti-HIV immunity through manipulation of Tfh function.R01AI106482 · NIAID · VGTI FLORIDA · PI HADDAD, ELIAS K · 2013 to 2017
$2.8M
CIHR 103230NIAID NIH HHS 1R01AI106482-01AINIAID NIH HHS AI064518NIAID NIH HHS P01 AI104722NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI064518NIAID NIH HHS P30AI36214NIAID NIH HHS R01 AI102766NIAID NIH HHS R01AI102766NIAID NIH HHS R01 AI106482NIAID NIH HHS T32 AI052077NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

Despite the overwhelming benefits of antiretroviral therapy (ART) in curtailing viral load in HIV-infected individuals, ART does not fully restore cellular and humoral immunity. HIV-infected individuals under ART show reduced responses to vaccination and infections and are unable to mount an effective antiviral immune response upon ART cessation. Many factors contribute to these defects, including persistent inflammation, especially in lymphoid tissues, where T follicular helper (Tfh) cells instruct and help B cells launch an effective humoral immune response. In this study we investigated the phenotype and function of circulating memory Tfh cells as a surrogate of Tfh cells in lymph nodes and found significant impairment of this cell population in chronically HIV-infected individuals, leading to reduced B cell responses. We further show that these aberrant memory Tfh cells exhibit an IL-2-responsive gene signature and are more polarized toward a Th1 phenotype. Treatment of functional memory Tfh cells with IL-2 was able to recapitulate the detrimental reprogramming. Importantly, this defect was reversible, as interfering with the IL-2 signaling pathway helped reverse the abnormal differentiation and improved Ab responses. Thus, reversible reprogramming of memory Tfh cells in HIV-infected individuals could be used to enhance Ab responses. Altered microenvironmental conditions in lymphoid tissues leading to altered Tfh cell differentiation could provide one explanation for the poor responsiveness of HIV-infected individuals to new Ags. This explanation has important implications for the development of therapeutic interventions to enhance HIV- and vaccine-mediated Ab responses in patients under ART.

Indexed as

HIVAdultAntibodies, ViralAntibody FormationB-LymphocytesCell DifferentiationCells, CulturedCellular ReprogrammingChronic DiseaseHIV InfectionsHumansImmunologic MemoryInterleukin-2Middle AgedSignal TransductionT-Lymphocytes, Helper-InducerAntibodies, ViralInterleukin-2

Identifiers

PMID26546609
PMCPMC4670798
OpenAlexW2172074761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.